Tags

Type your tag names separated by a space and hit enter

[A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection].

Abstract

The wide use of lamivudine in chronic hepatitis B has produced a monotonic increase in patients with lamivudine resistance. Therefore, treating lamivudine resistance in chronic hepatitis B is a major concern in clinical practice for the treatment of hepatitis B virus (HBV). There is conflicting evidence on the outcome of pegylated interferon alpha (PEG-IFN alpha) therapy against lamivudine-resistant HBV, which is due to mutations in the YMDD motif. We experienced a patient with chronic hepatitis B who was successfully treated with PEG-IFN alpha-2a after the development of virologic and biochemical breakthrough during lamivudine therapy. Virologic breakthrough was associated with the emergence of YMDD mutants 48 months after starting lamivudine therapy. Treatment with PEG-IFN alpha-2a for 12 months resulted in an undetectable serum level of HBV DNA and the resolution of hepatitis, and the virologic response was maintained over 16 months after cessation of PEG-IFN alpha-2a.

Links

Authors+Show Affiliations

,

Department of Internal Medicine, College of Medicine, The Catholic University of Korea, WHO Collaborating Center of Viral Hepatitis, Seoul, Korea.

, , , , ,

Source

The Korean journal of hepatology 14:4 2008 Dec pg 513-8

MeSH

Adult
Alanine Transaminase
Antiviral Agents
DNA, Viral
Drug Resistance, Viral
Hepatitis B, Chronic
Humans
Interferon alpha-2
Interferon-alpha
Lamivudine
Liver
Male
Polyethylene Glycols
Recombinant Proteins

Pub Type(s)

Case Reports
Journal Article

Language

kor

PubMed ID

19119246

Citation

Hur, Won Haing, et al. "[A Case Report of Treatment With Pegylated Interferon Alpha for Lamivudine-resistant Chronic Hepatitis B Virus Infection]." The Korean Journal of Hepatology, vol. 14, no. 4, 2008, pp. 513-8.
Hur WH, Woo HY, Jeong SW, et al. [A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection]. Korean J Hepatol. 2008;14(4):513-8.
Hur, W. H., Woo, H. Y., Jeong, S. W., You, C. R., Bae, S. H., Choi, J. Y., & Yoon, S. K. (2008). [A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection]. The Korean Journal of Hepatology, 14(4), pp. 513-8. doi:10.3350/kjhep.2008.14.4.513.
Hur WH, et al. [A Case Report of Treatment With Pegylated Interferon Alpha for Lamivudine-resistant Chronic Hepatitis B Virus Infection]. Korean J Hepatol. 2008;14(4):513-8. PubMed PMID: 19119246.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection]. AU - Hur,Won Haing, AU - Woo,Hyun Young, AU - Jeong,Soung Won, AU - You,Chan Ran, AU - Bae,Si Hyun, AU - Choi,Jong Young, AU - Yoon,Seung Kew, PY - 2009/1/3/entrez PY - 2009/1/3/pubmed PY - 2009/4/1/medline SP - 513 EP - 8 JF - The Korean journal of hepatology JO - Korean J Hepatol VL - 14 IS - 4 N2 - The wide use of lamivudine in chronic hepatitis B has produced a monotonic increase in patients with lamivudine resistance. Therefore, treating lamivudine resistance in chronic hepatitis B is a major concern in clinical practice for the treatment of hepatitis B virus (HBV). There is conflicting evidence on the outcome of pegylated interferon alpha (PEG-IFN alpha) therapy against lamivudine-resistant HBV, which is due to mutations in the YMDD motif. We experienced a patient with chronic hepatitis B who was successfully treated with PEG-IFN alpha-2a after the development of virologic and biochemical breakthrough during lamivudine therapy. Virologic breakthrough was associated with the emergence of YMDD mutants 48 months after starting lamivudine therapy. Treatment with PEG-IFN alpha-2a for 12 months resulted in an undetectable serum level of HBV DNA and the resolution of hepatitis, and the virologic response was maintained over 16 months after cessation of PEG-IFN alpha-2a. SN - 1738-222X UR - https://www.unboundmedicine.com/medline/citation/19119246/[A_case_report_of_treatment_with_pegylated_interferon_alpha_for_lamivudine_resistant_chronic_hepatitis_B_virus_infection]_ L2 - http://www.diseaseinfosearch.org/result/3332 DB - PRIME DP - Unbound Medicine ER -